We are live on ! Find out more
GC

Grimes & Company Portfolio holdings

AUM $4.62B
1-Year Est. Return 29.71%
This Fund
S&P 500
This Quarter Est. Return
-3.95%
1 Year Est. Return
+29.71%
3 Year Est. Return
+66.17%
5 Year Est. Return
+73.59%
10 Year Est. Return
+287.63%
AUM
$1.92B
AUM Growth
-$267M
Cap. Flow
-$176M
Cap. Flow %
-9.2%
Top 10 Hldgs %
36.15%
Holding
320
New
22
Increased
113
Reduced
115
Closed
20

Sector Composition

Rank Sector Weight
1 Technology 16.52%
2 Healthcare 10%
3 Financials 6.86%
4 Industrials 5.86%
5 Consumer Discretionary 4.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VEU icon
276
Vanguard FTSE All-World ex-US ETF
VEU
$66.9B
$213K 0.01%
3,692
-1,433
-28% -$84.3K
IWB icon
277
iShares Russell 1000 ETF
IWB
$49B
$210K 0.01%
839
-85
-9% -$21K
A icon
278
Agilent Technologies
A
$39.5B
$209K 0.01%
1,578
DOW icon
279
Dow Inc
DOW
$21.6B
$207K 0.01%
+3,248
New +$196K
ENPH icon
280
Enphase Energy
ENPH
$5.2B
$207K 0.01%
+1,025
New +$161K
GLW icon
281
Corning
GLW
$126B
$205K 0.01%
+5,559
New +$217K
OXY icon
282
Occidental Petroleum
OXY
$55.2B
$204K 0.01%
+3,590
New +$159K
IR icon
283
Ingersoll Rand
IR
$34.1B
$203K 0.01%
4,040
+100
+3% +$5.36K
ABMD
284
DELISTED
Abiomed Inc
ABMD
$203K 0.01%
614
RSP icon
285
Invesco S&P 500 Equal Weight ETF
RSP
$98.1B
$200K 0.01%
1,271
-80
-6% -$12.5K
ISPC icon
286
iSpecimen
ISPC
$2.89M
$187K 0.01%
+43
New +$168K
OCSL icon
287
Oaktree Specialty Lending
OCSL
$1.05B
$172K 0.01%
7,785
KNOP icon
288
KNOT Offshore Partners
KNOP
$370M
$169K 0.01%
+10,000
New +$154K
OBDC icon
289
Blue Owl Capital
OBDC
$5.46B
$162K 0.01%
+10,979
New +$161K
GBDC icon
290
Golub Capital BDC
GBDC
$3.44B
$160K 0.01%
+10,494
New +$162K
NAK
291
Northern Dynasty Minerals
NAK
$818M
$132K 0.01%
318,950
AVEO
292
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$108K 0.01%
19,380
ADMA icon
293
ADMA Biologics
ADMA
$2.03B
$98K 0.01%
53,314
-872
-2% -$1.36K
HRTX icon
294
Heron Therapeutics
HRTX
$96.8M
$86K ﹤0.01%
15,088
+3,561
+31% +$26.1K
ITRM
295
DELISTED
Iterum Therapeutics
ITRM
$63K ﹤0.01%
11,752
+1,963
+20% +$11.3K
MRSN
296
DELISTED
Mersana Therapeutics
MRSN
$57K ﹤0.01%
+575
New +$67.2K
RBBN icon
297
Ribbon Communications
RBBN
$379M
$31K ﹤0.01%
10,030
RGLS
298
DELISTED
Regulus Therapeutics
RGLS
$26K ﹤0.01%
8,820
+2,712
+44% +$7.06K
AGRX
299
DELISTED
Agile Therapeutics
AGRX
$23K ﹤0.01%
56
+14
+33% +$8.94K
CWBR
300
DELISTED
CohBar, Inc. Common Stock
CWBR
$6K ﹤0.01%
+633
New +$5.99K

Similar funds

Grimes & Company's Q1 2022 Portfolio in Review

As of Q1 2022, Grimes & Company held 320 positions worth $1.92B, down 12% from $2.18B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Grimes & Company withdrew a net $176M in Q1 2022, closing 20 positions and reducing 115 holdings. Its most notable exit was Xilinx Inc, an estimated $19M position sold in full.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Grimes & Company opened a new position in Advanced Micro Devices worth $16.6M.

  • Grimes & Company's largest Q1 2022 buy was Advanced Micro Devices: 151,681 shares worth $16.6M.
  • Grimes & Company added most to State Street Health Care Select Sector SPDR ETF in Q1 2022, an estimated $19.5M increase.
  • Grimes & Company's biggest Q1 2022 reduction was State Street Blackstone Senior Loan ETF, cutting an estimated $128M.
  • Grimes & Company fully exited Xilinx Inc in Q1 2022, selling an estimated $19M.
  • Grimes & Company's ten largest holdings make up 36% of its $1.92B portfolio in Q1 2022.
  • Grimes & Company opened 22 new positions and closed 20 in Q1 2022.
  • Grimes & Company's portfolio value fell 12% quarter-over-quarter to $1.92B.

Based on Grimes & Company's 13F filing for Q1 2022, filed 6 May 2022.